Summary
Introduction
The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.
Scope
- Country specific event-driven sales forecasts for the period 2006-15 for the US, Japan, France, Germany, Italy, Spain and the UK
- Discussion of recent trials and market-shaping future key events
- Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
- Case studies evaluating the commercial impact of two developmental agents with blockbuster potential
Highlights
Demographic trends lead to an increase in the patient population requiring antithrombotic therapy. However, the rising age of the population across all developed regions is increasing the fiscal burden on healthcare payors which are likely to respond by limiting the reimbursement potential of therapies and put pricing pressure on all agents.
The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents are subject to forthcoming genericization and will thus not contribute to the growth of the antithrombotics market in the medium-to-long term. Pipeline agents are expected to become significant drivers in the market.
The antithrombotics market is characterized by pockets of high unmet need and a broad spectrum of similarly efficacious therapeutic strategies. There is regional bias in the choice and popularity of therapeutic strategies driven by cultural reasons as well as infrastructural confines.
Reasons to Purchase
- Quantify future size and scope of the antithrombotics market and potential for new products
- Analyze options to expand commercial potential through pursuit of new indications
- Formulate successful launch strategies in a highly competitive mature market
|
